Yogurt consumption is a significant factor in reducing the risk of hypertension and preventing cardiovascular diseases. Although increasing evidence has emerged regarding the potential benefits of probiotics in hypertension, there is a lack of large, cross-sectional studies assessing the association between yogurt intake and blood pressure parameters. We aimed to evaluate the association between yogurt intake frequency and blood pressure. A cross-sectional study was designed using data from the National Health and Nutrition Examination Survey from 2003 to 2004 and 2005 to 2006. We included 3, 068 adults with blood pressure data and yogurt intake data. Multivariate regression analyses revealed significant inverse associations between yogurt and systolic blood pressure ( ), diastolic blood pressure ( ), and mean arterial pressure ( ) in nonhypertensive participants (n = 1 822) but not in hypertensive participants (n = 1 246). Furthermore, a high frequency of yogurt intake prevented hypertension; however, no additional antihypertensive effects were observed in patients already diagnosed with hypertension.
24 September 2025 in Reviews in Cardiovascular Medicine
Background: Magnesium deficiency represents a prevalent electrolyte imbalance that notably heightens the risk of adverse cardiovascular incidents among individuals with heart failure. Research indicates that magnesium supplementation can diminish the frequency of negative events linked to hypomagnesemia in heart failure patients, while also enhancing the outcomes for critically ill individuals. Nevertheless, there remains a scarcity of studies investigating the effects of intravenous magnesium supplementation on mortality risk in those suffering from acute heart failure. This study aimed to explore the relationship between the administration of intravenous magnesium sulfate and the overall mortality risk in patients with acute heart failure who are admitted to intensive care units. Methods: This retrospective cohort study employed the Medical Information Mart for Intensive Care IV (MIMIC-IV) database (version 3.1), which encompasses the baseline clinical data of 10,031 patients diagnosed with acute heart failure. Propensity score matching and multivariate Cox regression analysis were utilized to assess the effects of intravenous magnesium sulfate on 28-day all-cause mortality. The evaluation of unmeasured confounding variables was undertaken through E-value calculations, while subgroup analyses were performed to ascertain the robustness of the results. Results: A total of 10,031 patients participated in the study, with 6240 belonging to the propensity-score matched group, which included 3120 subjects who received intravenous magnesium sulfate and 3120 who did not. The entire cohort consisted of 10,031 individuals, whereas the matched cohort specifically comprised 6240 patients. Within the matched group, the rates of 28-day all-cause mortality were observed to be 13.2% (413/3120) for those administered intravenous magnesium sulfate, compared to 15.8% (493/3120) for the control group. Administration of intravenous magnesium sulfate correlated with a significantly reduced risk of 28-day all-cause mortality (hazard ratio (HR), 0.81; 95% confidence interval (CI), 0.71–0.93; p = 0.004). A sensitivity analysis conducted on the entire cohort corroborated this association (HR, 0.77; 95% CI, 0.69–0.87; p < 0.001). Additional subgroup analyses and E-value assessments reinforced the relevance of these results. Furthermore, intravenous magnesium sulfate was linked to reduced all-cause mortality at both 90 and 365 days. Conclusions: Intravenous magnesium sulfate appears to decrease all-cause mortality in patients with acute heart failure, while further prospective studies are warranted to validate these results.
Background: Approximately one-quarter of adults have a patent foramen ovale (PFO). Migraine is the second most prevalent neurological disorder. The potential causal relationship between PFO and migraine has been a subject of ongoing debate. This study aims to investigate the genetic association between PFO and migraine. Materials and methods: This study utilized aggregated data from the Finnish database to explore the genetic causal relationship between PFO as an exposure factor and migraine as an outcome factor. We employed a MR design, with inverse variance weighting (IVW) as the primary analysis method, supplemented by MR-Egger regression. Sensitivity analyses included Cochran Q tests, MR-Egger intercept analysis, leave-one-out analysis, and funnel plots. Results: After screening, we selected four single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) for the Mendelian randomization analysis. The IVW analysis revealed statistically significant associations between PFO and five subtypes of migraine: overall migraine (OR = 1.0531, P = 0.0253), migraine with aura (OR = 1.0809, P = 0.0227), triptan use in patients with migraine with aura (OR = 1.0986, P = 0.0355), migraine without aura (OR = 1.0906, P = 0.0209), and triptan use in patients with migraine without aura (OR = 1.1043, P = 0.0220). No evidence of horizontal pleiotropy was detected in the MR-Egger intercept analysis. These findings enhance our understanding of the relationship between PFO and migraine. Conclusion: This study provides preliminary evidence of a positive causal association between PFO and migraine. The analysis suggests that PFO may be associated with an increased risk of migraine.